Vir Biotechnology, Inc.
VIR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $74 | $86 | $1,616 | $1,095 |
| % Growth | -13.9% | -94.7% | 47.5% | – |
| Cost of Goods Sold | $479 | $573 | $621 | $514 |
| Gross Profit | -$404 | -$487 | $995 | $582 |
| % Margin | -545% | -564.7% | 61.6% | 53.1% |
| R&D Expenses | $506 | $580 | $475 | $448 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$324 | -$382 | -$313 | -$287 |
| Operating Expenses | $183 | $198 | $162 | $161 |
| Operating Income | -$587 | -$684 | $833 | $421 |
| % Margin | -791.3% | -794% | 51.6% | 38.4% |
| Other Income/Exp. Net | $64 | $56 | -$79 | $129 |
| Pre-Tax Income | -$523 | -$628 | $754 | $550 |
| Tax Expense | -$1 | -$13 | $238 | $21 |
| Net Income | -$522 | -$615 | $516 | $529 |
| % Margin | -703.4% | -713.7% | 31.9% | 48.3% |
| EPS | -3.83 | -4.59 | 3.89 | 4.07 |
| % Growth | 16.6% | -218% | -4.4% | – |
| EPS Diluted | -3.83 | -4.59 | 3.83 | 3.96 |
| Weighted Avg Shares Out | 136 | 134 | 133 | 130 |
| Weighted Avg Shares Out Dil | 136 | 134 | 135 | 133 |
| Supplemental Information | – | – | – | – |
| Interest Income | $72 | $87 | $28 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $15 | $19 | $7 | $6 |
| EBITDA | -$509 | -$642 | $840 | $427 |
| % Margin | -685.8% | -744.5% | 52% | 38.9% |